MX2024008642A - Composiciones de citocinas dise?adas y metodos de uso. - Google Patents

Composiciones de citocinas dise?adas y metodos de uso.

Info

Publication number
MX2024008642A
MX2024008642A MX2024008642A MX2024008642A MX2024008642A MX 2024008642 A MX2024008642 A MX 2024008642A MX 2024008642 A MX2024008642 A MX 2024008642A MX 2024008642 A MX2024008642 A MX 2024008642A MX 2024008642 A MX2024008642 A MX 2024008642A
Authority
MX
Mexico
Prior art keywords
methods
designed
loop
connects
cytokine compositions
Prior art date
Application number
MX2024008642A
Other languages
English (en)
Spanish (es)
Inventor
Brian Weitzner
Scott Boyken
Marc Lajoie
Thaddeus M Davenport
Howell Moffett
Andrew Howen Ng
Paul Joseph Sample
Original Assignee
Outpace Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Outpace Bio Inc filed Critical Outpace Bio Inc
Publication of MX2024008642A publication Critical patent/MX2024008642A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2024008642A 2022-01-11 2023-01-11 Composiciones de citocinas dise?adas y metodos de uso. MX2024008642A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263298623P 2022-01-11 2022-01-11
US202363479176P 2023-01-09 2023-01-09
US202363479178P 2023-01-09 2023-01-09
US202363479177P 2023-01-09 2023-01-09
PCT/US2023/060508 WO2023137346A2 (en) 2022-01-11 2023-01-11 Designed cytokine compositions and methods of use

Publications (1)

Publication Number Publication Date
MX2024008642A true MX2024008642A (es) 2024-09-23

Family

ID=87279672

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008642A MX2024008642A (es) 2022-01-11 2023-01-11 Composiciones de citocinas dise?adas y metodos de uso.

Country Status (10)

Country Link
US (1) US20250223330A1 (cg-RX-API-DMAC10.html)
EP (1) EP4463469A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025502205A (cg-RX-API-DMAC10.html)
KR (1) KR20240164594A (cg-RX-API-DMAC10.html)
CN (1) CN119053616A (cg-RX-API-DMAC10.html)
AU (1) AU2023208031A1 (cg-RX-API-DMAC10.html)
CA (1) CA3248134A1 (cg-RX-API-DMAC10.html)
IL (1) IL314226A (cg-RX-API-DMAC10.html)
MX (1) MX2024008642A (cg-RX-API-DMAC10.html)
WO (1) WO2023137346A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL325764A (en) * 2023-07-13 2026-03-01 Outpace Bio Inc Designed interleukin-2 cytokine compositions and methods for use
WO2025212606A1 (en) * 2024-04-01 2025-10-09 Bio-Techne Corporation Synthetic il-2 polypeptides and conjugates, compositions, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020025287A2 (pt) * 2018-06-25 2021-03-09 University Of Washington Projeto de novo de miméticos de interleucina potentes e seletivos
US12522640B2 (en) * 2018-07-24 2026-01-13 BioNTech SE IL2 agonists
WO2023131270A1 (en) * 2022-01-07 2023-07-13 Cure Genetics, Co., Limited Novel interleukin-2 polypeptides

Also Published As

Publication number Publication date
EP4463469A4 (en) 2026-01-14
KR20240164594A (ko) 2024-11-19
JP2025502205A (ja) 2025-01-24
CA3248134A1 (en) 2023-07-20
IL314226A (en) 2024-09-01
WO2023137346A3 (en) 2023-11-16
CN119053616A (zh) 2024-11-29
WO2023137346A2 (en) 2023-07-20
US20250223330A1 (en) 2025-07-10
EP4463469A2 (en) 2024-11-20
AU2023208031A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
WO2023137346A3 (en) Designed cytokine compositions and methods of use
PH12021552162A1 (en) Liquid composition comprising antibody of human interleukin-4 receptor alpha
MX2026000396A (es) Composiciones de citocinas interleucina-2 diseñadas y métodos para su uso
ZA202109587B (en) Glucagon-like peptide 1 receptor agonists
MX2023004349A (es) Anticuerpos monoclonales anti-ccr8 y sus usos.
MX2024000611A (es) Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso.
BR112021017365A2 (pt) Receptores de citocina quiméricos constitutivamente ativos
AU2021359068A8 (en) Caninized antibodies to canine interleukin-31 receptor alpha
EA202190593A1 (ru) Расщепленные миметики интерлейкина и их применение
WO2021188374A3 (en) Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
MX2023009995A (es) Composiciones que incluyen adyuvantes de sbi y metodos para usarlos.
ZA202208051B (en) Protein degradation agent compound preparation method and application
MX2020014027A (es) Dise?o de novo de mimeticos de interleucina potentes y selectivos.
MX2026002776A (es) Proteinas de union al antigeno biespecificas anti-receptor de cgrp/anti-receptor pac1
EP4595950A3 (en) Annexin a1 n-terminal peptide formulations and methods
CR20240462A (es) Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos
MX2024007393A (es) Complejos polipeptidicos de union a antigeno activados condicionalmente y metodos de uso de los mismos.
CA3156452A1 (en) NPY2 RECEPTOR AGONISTS
WO2020108629A8 (zh) 一种多肽rdp1及其提纯方法与应用
CO2025009746A2 (es) Antagonistas de citocinas multivalentes y multiespecíficos
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
ATE308335T1 (de) Histidine-rich glycoprotein (hrgp) zur hemmung der angiogenese
EP2431050A8 (en) Methods of treating cancer using IL-21 and monoclonal antibody therapy
WO2020073835A8 (zh) 白介素-6的人源化单克隆抗体、其编码基因及应用
ATE339447T1 (de) Hochaffine antagonisten der elr-cxc chemokine